Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 5/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019114 | 1.00 | SIGMAR1 (0.38) | SIGMAR1KDRMGLLOPRD1OPRK1 | |
| SCHEMBL4022006 | 0.95 | SIGMAR1 (0.37) | SIGMAR1KDRMGLLOPRD1OPRK1 | |
| SCHEMBL4022000 | 0.95 | SIGMAR1 (0.37) | SIGMAR1KDRMGLLOPRD1OPRK1 | |
| SCHEMBL4021764 | 0.89 | MGLL (0.36) | MGLLOPRD1OPRK1BCHETLR9 | |
| SCHEMBL4021758 | 0.89 | MGLL (0.36) | MGLLOPRD1OPRK1BCHETLR9 | |
| SCHEMBL4022425 | 0.88 | KIF11 (0.42) | KDRMGLLOPRD1OPRK1BCHE | |
| SCHEMBL4019102 | 0.87 | ACHE (0.37) | KDRMGLLBCHEACHE | |
| SCHEMBL4025347 | 0.87 | KIF11 (0.37) | KDRBCHEACHE | |
| SCHEMBL4023151 | 0.86 | HTR7 (0.37) | KDRBCHEACHE | |
| SCHEMBL4022333 | 0.86 | BCHE (0.36) | MGLLOPRD1OPRK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | SIGMAR1 3578/4885KDR 4166/4885MGLL 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.